Linezolid versus vancomycin for prosthetic joint infections: A cost analysis

Infection

Volumn 35, Issue 4, 2007, Pages 265-270

  You, J H S ^a   Lee, G C H ^a   So, R K H ^a   Cheung, K W ^b   Hui, M ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; METICILLIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BONE MARROW SUPPRESSION; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAM POSITIVE BACTERIUM; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HOME CARE; HONG KONG; HOSPITAL PATIENT; HUMAN; LACTIC ACIDOSIS; MONTE CARLO METHOD; OUTPATIENT; PENICILLIN RESISTANCE; PROSTHESIS INFECTION;

ACETAMIDES; ADMINISTRATION, ORAL; ALGORITHMS; ANTI-BACTERIAL AGENTS; COSTS AND COST ANALYSIS; GRAM-POSITIVE BACTERIAL INFECTIONS; HEALTH CARE COSTS; HOME CARE SERVICES; HUMANS; INFUSIONS, INTRAVENOUS; JOINT PROSTHESIS; METHICILLIN RESISTANCE; OXAZOLIDINONES; PROSTHESIS-RELATED INFECTIONS; VANCOMYCIN;

EID: 34547683496     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-007-6304-8     Document Type: Article

References (18)

1. Zimmerli W, Trampuz A, Ochsner PE: Current concepts: prosthetic-joint infections. N Engl J Med 2004; 351: 1645-1654.
2. Duggan JM, Georgiadis GM, Kleshinski JF: Management of prosthetic joint infections. Infect Med 2001; 18: 534-541.
3. Widmer AF: New developments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis 2001; 33: S94-S106.
4. Bernard L, Hoffmeyer P, Assal M, et al. Trends in the treatment of orthopaedic prosthetic infections. J Antimicrob Chemother 2004; 53: 127-129.
5. Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assessment of linezolid's clinical safety and tolerability: comparatorcontrolled phase III studies. Amtimicrob Agents Chemother 2003; 47: 1824-1831.
6. Border KW, Moise PA, Schultz RO, et al. Clinical experience with linezolid in conjunction with wound coverage techniques for skin and soft-tissue infections and postoperative osteomyelitis. Ann Plast Surg 2004; 52: 385-390.
7. The American Thoracic Society and the Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcareassociated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
8. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A: High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-2144.
9. Bernard L, El-Hajj, Pron B et al: Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis: evaluation of efficacy, tolerance and cost. J Clin Pharm Ther 2001; 26: 445-451.
10. Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003; 36: 159-168.
11. Rayner CR, Baddour LM, Birmingham MC, et al. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection 2004; 32: 8-14.
12. Rao N, Ziran BH, Hall RA, et al. Successful treatment of chronic bone and joint infections with oral linezolid. Clin Orthop Relat R 2004; 427: 67-71.
13. Razonable RR, Osmon DR, Steckelberg JM: Linezolid therapy for orthopedic infections. Mayo Clin Pro 2004; 79: 1137-1144.
14. Aneziokoro CO, Cannon JP, Pachucki CT, et al. The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis. J Chemother 2005; 17: 643-650.
15. Vuagnat A, Stern R, Lotthe A, et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther 2004; 29: 351-357.
16. Boffi El Amari E, Vuagnat A, Stern R, et al. High versus standard dose vancomycin for osteomyelitis. Scand J Infect Dis 2004; 36: 712-717.
17. Website: http://www.info.gov.hk (assessed in April 2006).
18. Nathwani D, Barlow GD, Ajdukiewicz K, et al. Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, inpatient care or outpatient oral linezolid therapy. J Antimicrob Chemother 2003; 51: 391-396.